# Sonesitatug vedotin

Source: https://onco.cc/drugs/cmg901/  
OnCo record `cmg901` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sonesitatug vedotin is a Claudin 18.2 ADC in phase 3 for gastric cancer, licensed by AstraZeneca from KYM Biosciences.

## Summary

Sonesitatug vedotin (CMG901) is an anti-Claudin 18.2 antibody carrying the microtubule inhibitor MMAE through a cleavable linker; Claudin 18.2 is a tight-junction protein normally buried in gastric mucosa but exposed on gastric and some pancreatic cancer cells, giving the ADC a tumour-selective address. AstraZeneca licensed global rights from KYM Biosciences in 2023. Phase 1 produced an objective response rate around 33 percent in CLDN18.2-positive gastric cancer, and the CLARITY-Gastric01 phase 3 trial is testing it at 2.2 mg/kg every 3 weeks in second-line gastric cancer. Nausea, vomiting, neutropenia and decreased appetite are the main toxicities, the gut effects reflecting on-target binding to normal stomach lining. It competes with XNW27011 and other CLDN18.2 ADCs, so randomised data will decide the field. It delivers a cell poison to a protein hidden in healthy tissue.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-04
- Code: CMG901, AZD0901
- Modality: ADC
- Mechanism: Anti-CLDN18.2 with MMAE.
- Payload: MMAE
- Linker: Cleavable
- Dosing: IV infusion; 2.2 mg/kg every 3 weeks (phase 3 dose)

## Sources

- ClinicalTrials.gov: trials of Sonesitatug vedotin: https://clinicaltrials.gov/search?intr=CMG901

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Claudin 18.2-positive gastric cancer](https://onco.cc/cancers/gastric-cldn18-2-positive/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Keymed Biosciences (KYM Biosciences)](https://onco.cc/companies/keymed/)
- trials: [A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma](https://onco.cc/trials/nct07069712/), [AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2](https://onco.cc/trials/nct06219941/), [CLARITY-Gastric 01](https://onco.cc/trials/clarity-gastric01/), [Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2](https://onco.cc/trials/nct07431281/)
- pairings: [CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression](https://onco.cc/pairings/cldn18-antibody-then-adc/)
- terms: [MMAE](https://onco.cc/terms/mmae/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)

---
JSON: https://onco.cc/api/v1/entities/cmg901.json